Compare · LBPH vs NVO
LBPH vs NVO
Side-by-side comparison of Longboard Pharmaceuticals Inc. (LBPH) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LBPH and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $180.22B.
- NVO has hit the wire 9 times in the past 4 weeks while LBPH has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 7 for LBPH).
- Company
- Longboard Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- -
- $180.22B
- 1M return
- -
- +5.96%
- 1Y return
- -
- -14.37%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 9
- Recent ratings
- 7
- 25
Longboard Pharmaceuticals Inc.
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LBPH
- Sensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual Report
- Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director
- SEC Form 15-12G filed by Longboard Pharmaceuticals Inc.
- SEC Form POSASR filed by Longboard Pharmaceuticals Inc.
- SEC Form RW WD filed by Longboard Pharmaceuticals Inc.
- SEC Form EFFECT filed by Longboard Pharmaceuticals Inc.
- SEC Form EFFECT filed by Longboard Pharmaceuticals Inc.
- SEC Form EFFECT filed by Longboard Pharmaceuticals Inc.
- SEC Form 4 filed by Director Lynch Casey
- SEC Form 4 filed by Director Le Goff Corinne
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S